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INTRODUCTION 
The mechanism underlying myocardial stunning is still unknown, but current 
views hold that generation offree radicals and disturbances in the calcium homeostasis, 
mechanisms which are not mutually exclusive, are the two most likely causes of pro- 
longed postischemic dysfunction. 1.2 Several groups of investigators have indeed 
shown that the capacity of cardiac sarcoplasrnic reticulum (SR) to sequester Ca2+ de- 
creases during i~chernia.~.~ In a recent study we have shown that the phosphorylation 
rate of phospholamban was unchanged, and that Ca2+ uptake by the sarcoplasmic re- 
ticulum was even slightly increased in myocardium of intact open-chest pigs, while 
function was still reversibly depressed.5 These data and earlier work by Marban and 
coworkers6 in isolated stunned ferret hearts strongly suggest that a decreased response 
of the myofilaments to Ca2+ rather than a change in the active Ca2+ transport of the 
SR is involved in the contractile dysfunction of stunned myocardium. In vivo evidence 
of this hypothesis has been very difficult to obtain because available agents that increase 
the responsiveness of the myofilaments to Ca2+ usually also increase contractility via 
inhibition of phosphodiesterase. We now report on the effects of the thiadiazinone 
derivative EMD 60263, which in in vitro experiments has been shown to be a potent 
Ca2+ sensitizer devoid of any phosphodiesterase inhibiting properties (Ravens et al., 
unpublished data). The compound also affects the delayed rectifier current I K ~  in a 
way characteristic for a class I11 antiarrhythmic action. The latter property may lead 
to a reduction in heart rate. 
To whom correspondence should be addressed. 
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MATERIALS AND METHODS 
Pigs (28-30 kg) were anesthetized and instrumented as described earlier.' After a 
stabilization period the left anterior descending coronary artery (LADCA) was oc- 
cluded for 10 min and reperfused for 30 min. This sequence of occlusion and reper- 
fusion was then repeated. At the end of the second 30-min reperfusion period, two 
consecutive infusions of either saline (3 ml and 6 ml; n = 6) or EMD 60263 (1.5 mg/kg 
and 3.0 mg/kg, n = 7; courtesy of Dr. I. Lues and Prof. Dr. P. Schelling, E. Merck, 
Darmstadt, FRG) were administered a t  15-min intervals and the effects on systemic 
hemodynamics, regional myocardial segment length shortening (SLS) of the myocar- 
dium perfused by the LADCA and the left circumflex coronary artery (LCXCA), and 
regional myocardial blood flow were measured. The area of the pressure-segment 
length loop was calculated as an index of external work (EW),8 while the mechanical 
efficiency was determined as the ratio of EW and MVOz, in which the MVOz is the 
regional myocardial oxygen consumption ( i t . ,  the product of regional transmural 
myocardial blood flow and the difference in the arterial and local coronary venous 
oxygen content). 
TABLE 1. The Effects of EMD 60263 o n  Systemic Hemodynamics in Anesthe- 
tized Pigs with Stunned Myocardium 
3 ml 6 ml 
EMD 60263 Baseline Stunning 1.5 mg/kg 3.0 mg/kg 
Heart rate Saline 107 f 3 103 f 7 103 f 8 101 f 8 
(beatshin) EMD 60263 107 f 5 97 f 3" 69 f 2t# 50 f 3t# 
Systolic arterial Saline 109 f 2 101 f 3" 101 f 2 107 f 3t 
pressure (mm Hg) EMD 60263 114 f 2 108 f 3 106 f 3 111 f 4 
Diastolic arterial Saline 77 f 2 73 f 3" 72 f 2 75 f 2 
pressure (mm Hg) EMD 60263 83 f 3 79 f 4 67 f 4+# 62 f j t#  
Cardiac output Saline 2 . 9 f 0 . 3  2 . 4 f 0 . 1 *  2 . 4 f 0 . 2  2 . 4 f 0 . 1  
(L/min) EMD 60263 2.9 f 0.1 2.5 f 0.1" 2.3 f 0.1 2.2 f O.lt 
Stroke volume Saline 27 f 2 23 f 1 23 f 1 24 f 1 
Systemic vascular Saline 32 f 3 35 f 2' 35 f 3 36 f 3 
resistance EMD 60263 33 f 3 36 f 3 36 f 3 36 f 3 
(mm Hg.min/L) 
Left ventricular Saline 2070 f 220 1580 f 180" 1600 f 170 1640 f 160 
dP/dtmax EMD 60263 2130 f 150 1580 f 110" 1520 f 110 1630 f 100 
(mm Hglsec) 
diastolic pressure EMD 60263 10 f 1 10 f 1 11 f 1 14 f 2t 
n = 6 for the saline-treated animals; n = 7 for the EMD 60263-treated animals; " p < 0.05 
p < 0.05 versus stunning; # Changes versus stunning are significantly 
(4 EMD60263 27 f 2 26 f 1 33 f 2t# 45 f 3t# 
Left ventricular end Saline 8 + 1  9 f l  8 f l  10 f 2 
(mm Hg) 
stunning versus baseline; 
different from changes versus stunning in saline-treated animals; Data are mean f SEM. 
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FIGURE 1. The effects of EMD 60263 on segment length shortening (SLS) and external work 
(EW) of the myocardium perfused by the left anterior descending coronary artery (LADCA) and 
the myocardium perfused by the left circumflex coronary artery (LCXCA) and the mechanical 
efficiency (EWIMv02) of the LADCA-perfused myocardium. n = 6 for the dine-treated ani- 
mils; n = 7 for the EMD 60263-treated animals; * p < 0.05 stunning versus baseline; + p < 0.05 
versus stunning; changes versus stunning are significantly different from changes versus stun- 
ning in saline-treated animals. Data are mean f SEM. 
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RESULTS AND DISCUSSION 
Induction of myocardial stunning was accompanied by the well-described changes 
in systemic hemodynamic variables ~ B L E  1). In the saline-treated animals there 
were no further changes in any of these variables during the following 30 min. Ad- 
ministration of EMD 60263 caused a number of changes of which the decreases in 
heart rate and diastolic arterial pressure and the increase in stroke volume were the 
most pronounced. 
An additional consequence of the occlusion-reperfusion protocol was that in the 
stunned myocardium systolic SLS, EW, and the EWIMVO2 were reduced by approx- 
imately 50% (FIG. 1). No changes occurred in the area perfused by the LCXCA. All 
regional function variables remained stable in the saline-treated animals during the fol- 
lowing 30 min (FIG. 1). In the stunned myocardium, administration of EMD 60263 
caused dose-dependent increases in all variables, with the values for SLS and EW ex- 
ceeding the data obtained at baseline. In the control segment some variables also in- 
creased, but, most importantly, all differences in the variables between the stunned 
and the control regions disappeared. 
In order to exclude that changes in regional function were secondary to changes 
in heart rate or adrenergic stimulation, we studied in separate experiments, using the 
same model, the effects of the specific negative chronotropic drug zatebradine (UL-FS 
49)9 and the effects of EMD 60263 after blockade of the a- and 0-adrenoceptors and 
observed that bradycardia did not improve function of the stunned myocardium 
and that adrenergic stimulation did not contribute to the effect of EMD 60263. 
We conclude that these experiments, although not providing definite proof, lend 
further support to the hypothesis that a decrease in the sensitivity of the myofilaments 
to Ca2+ plays a role in the mechanism leading to myocardial stunning. 
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